Overview

Study Evaluating rhIL-11 in Active Crohn's Disease

Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the activity of multiple doses of oral rhIL-11 in patients with active Crohn's disease (Crohn's Disease Activity Index [CDAI] score from 220-400).
Phase:
Phase 2
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Oprelvekin